Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville Affiliate
TRIB•Trinity Biotech formally terminated its standby equity purchase agreement with financing partner Yorkville affiliate YA II PN, Ltd., ending access to an undisclosed equity line of credit. The move reflects the company’s revised financing strategy and signals confidence in its cash position and future funding plans.
1. Termination of SEPA
Trinity Biotech delivered formal notice to YA II PN, Ltd., an affiliate of Yorkville Advisors, to terminate its Standby Equity Purchase Agreement, thereby closing its option to draw on the SEPA equity line of credit.
2. Financing Strategy Shift
The company’s decision to end the SEPA aligns with its updated financing strategy, underscoring confidence in current cash reserves and a preference for internal funding over equity-based financing.
3. Potential Financial Benefits
By foregoing the standby equity facility, Trinity Biotech reduces the risk of future shareholder dilution and avoids associated issuance costs, supporting a more stable capital structure.
